Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 91,700 shares, a drop of 33.8% from the November 30th total of 138,600 shares. Based on an average daily volume of 2,921,900 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. Five analysts have rated the stock with a hold rating, According to MarketBeat, Bayer Aktiengesellschaft has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Price Performance

OTCMKTS:BAYRY traded up $0.12 during midday trading on Friday, hitting $4.97. 2,492,553 shares of the stock were exchanged, compared to its average volume of 1,446,597. The company has a market capitalization of $19.53 billion, a price-to-earnings ratio of -19.12 and a beta of 1.03. The company has a current ratio of 1.32, a quick ratio of 0.81 and a debt-to-equity ratio of 1.19. Bayer Aktiengesellschaft has a one year low of $4.79 and a one year high of $9.79. The business has a 50-day moving average price of $5.66 and a two-hundred day moving average price of $6.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.10). The firm had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. Sell-side analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.